Ozanimod (Zeposia) approved for relapsing remitting MS in Scotland
8 February 2021
The MS Trust is delighted that ozanimod (Zeposia) has been approved in Scotland for people with active relapsing remitting multiple sclerosis.
Exercise is good for your brain
3 February 2021
There is more to exercise than physical fitness. This review looks at recent research which shows how exercise has a direct beneficial effect on brain repair processes.
Covid-19 vaccines and MS: Part two
29 January 2021
Following our last interview on the subject of the Covid-19 vaccine and people with MS, we received a lot of follow up questions. To answer some of these, we spoke once again to Professor Alasdair Coles, Consultant Neurologist at Addenbrooke’s hospital.
Ozanimod (Zeposia) for relapsing remitting multiple sclerosis rejected by NICE
22 January 2021
The MS Trust is very disappointed that NICE does not recommend ozanimod (Zeposia) as an NHS treatment in England and Wales.
Researchers develop mRNA vaccine to treat MS-like condition in mice
14 January 2021
A potential treatment for multiple sclerosis uses mRNA technology, similar to two of the Covid-19 vaccines. Find out more about this research.
Daytime sleepiness and driving in MS
6 January 2021
In this study, researchers compared daytime sleepiness while driving in people with and without MS.
Remyelination research: what it means for people with MS
22 December 2020
Most people with MS will have heard of demyelination but perhaps not remyelination. We spoke with Dr Nick Cunniffe, who has been involved in some of the recent remyelination research, to find out more.
Covid-19 vaccine and MS: Your questions answered
8 December 2020
There's been a lot of interest around the new Covid-19 vaccines and how they might affect people with multiple sclerosis (MS). We've collected some common questions and answers from the MS Trust Enquiry Service this week to share with you.
When will people with MS get a Covid-19 vaccine?
2 December 2020
The MHRA has approved a Covid-19 vaccine, and the government and NHS are preparing to deliver a mass vaccination programme in the UK. Where do people with multiple sclerosis (MS) fit into the priority list?
Covid-19 vaccines: what they mean for people with MS
12 November 2020
We speak to a neurologist about whether a future Covid-19 vaccine would be safe and effective for people with MS.
A round-up of research from MS Virtual 2020
4 November 2020
An update from the this ECTRIMS and ACTRIMS which is the largest annual MS research conference.
Siponimod (Mayzent) approved for active secondary progressive MS in England and Wales
15 October 2020
The MS Trust is delighted that siponimod (Mayzent) has also been approved by NICE in England and Wales.